ESMO 2023: Does stopping VEGFR TKI treatment and continuing immunotherapy influence the survival of patients on combination therapy?
In many countries, combinations of VEGFR TKI anti-cancer mediations plus [...]
ESMO 2023: A new immunotherapy, volrustomig, for the first-line treatment of advanced kidney cancer
Blocking the action of two proteins in cancer cells (PD-1 [...]
ESMO 2023: A new first-line treatment, toripalimab, for advanced kidney cancer
Advanced/metastatic kidney cancer is often treated with a combination of [...]
ESMO 2023: Belzutifan for the treatment of advanced kidney cancer
Treatments for people with metastatic kidney cancer have changed over [...]
Action Kidney Cancer at the ESMO Congress
Steve Pointon, person centred counsellor kidney cancer patient and one of [...]
Patients with metastatic kidney cancer on immunotherapy may benefit from nephrectomy
Surgery to remove the kidney and tumour (nephrectomy) has an [...]
Injectable form of nivolumab
An injectable form of nivolumab has been successful in clinical [...]
Little Big Things from Every Mind Matters
Today (Tuesday 10th October) is World Mental Health Day. Every [...]
SMC approves belzutifan for VHL kidney cancer in Scotland
We are delighted to announce that the Scottish Medicines Consortium [...]
Kidney function 5 years after SABR for primary kidney cancer
Stereotactic ablative body radiotherapy (SABR) uses high doses of radiation [...]
